PMID- 21296193
OWN - NLM
STAT- MEDLINE
DCOM- 20111004
LR  - 20151119
IS  - 1873-0183 (Electronic)
IS  - 1568-9972 (Linking)
VI  - 10
IP  - 8
DP  - 2011 Jun
TI  - Does polymorphysm of genes coding for pro-inflammatory mediators predict the 
      clinical response to tnf alpha blocking agents? A review analysis of the 
      literature.
PG  - 460-3
LID - 10.1016/j.autrev.2011.01.010 [doi]
AB  - Tumor necrosis factor-alpha (TNF-alpha) has a key role in the pathogenesis of rheumatoid 
      arthritis (RA) and the introduction of anti-TNFalpha biological therapies has 
      dramatically altered the treatment of RA. Anti-TNFalpha agents display good clinical 
      efficacy in patients resistant to traditional disease-modifying antirheumatic 
      drugs and superior efficacy in the suppression of erosive joint damage, even if a 
      significant non-response rate has been reported (30-40%). Because anti-TNFalpha 
      therapy is associated with expensive treatment costs, leading to restrictions in 
      the numbers of patients who may be treated, the identification of predictors of 
      treatment outcome may improve the cost-effectiveness of anti-TNFalpha therapies. 
      Several candidate gene studies have addressed this topic, but they have had 
      limited success in identifying predictors. It is not clear whether the response 
      to anti-TNFalpha treatment will be conferred through a number of genes, each with a 
      small effect size, or whether genes may predict the outcome of the treatment.
CI  - Copyright (c) 2011. Published by Elsevier B.V.
FAU - Ingegnoli, Francesca
AU  - Ingegnoli F
AD  - Division of Rheumatology, Istituto Gaetano Pini, University of Milan, Italy.
FAU - Favalli, Ennio Giulio
AU  - Favalli EG
FAU - Meroni, Pier Luigi
AU  - Meroni PL
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20110204
PL  - Netherlands
TA  - Autoimmun Rev
JT  - Autoimmunity reviews
JID - 101128967
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Biomarkers, Pharmacological)
RN  - 0 (Inflammation Mediators)
RN  - 0 (Tumor Necrosis Factor-alpha)
SB  - IM
MH  - Antirheumatic Agents/pharmacology/*therapeutic use
MH  - Arthritis, Rheumatoid/*diagnosis/drug therapy/*genetics
MH  - Biomarkers, Pharmacological/*metabolism
MH  - Clinical Trials as Topic
MH  - Genetic Association Studies
MH  - Humans
MH  - Inflammation Mediators/*metabolism
MH  - Pharmacogenetics
MH  - Polymorphism, Genetic
MH  - Precision Medicine
MH  - Prognosis
MH  - Tumor Necrosis Factor-alpha/antagonists & inhibitors
EDAT- 2011/02/08 06:00
MHDA- 2011/10/05 06:00
CRDT- 2011/02/08 06:00
PHST- 2011/01/12 00:00 [received]
PHST- 2011/01/29 00:00 [accepted]
PHST- 2011/02/08 06:00 [entrez]
PHST- 2011/02/08 06:00 [pubmed]
PHST- 2011/10/05 06:00 [medline]
AID - S1568-9972(11)00025-5 [pii]
AID - 10.1016/j.autrev.2011.01.010 [doi]
PST - ppublish
SO  - Autoimmun Rev. 2011 Jun;10(8):460-3. doi: 10.1016/j.autrev.2011.01.010. Epub 2011 
      Feb 4.